tetano
Editor, Senior Moderator
Int J Mol Sci
. 2021 Dec 14;22(24):13445.
doi: 10.3390/ijms222413445.
Protein-Based Nanoparticle Vaccines for SARS-CoV-2
Hyo-Dong Sung[SUP] 1 [/SUP], Nayeon Kim[SUP] 1 [/SUP], Yeram Lee[SUP] 1 [/SUP], Eun Jung Lee[SUP] 1 [/SUP]
Affiliations
Abstract
The pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has upended healthcare systems and economies around the world. Rapid understanding of the structural biology and pathogenesis of SARS-CoV-2 has allowed the development of emergency use or FDA-approved vaccines and various candidate vaccines. Among the recently developed SARS-CoV-2 candidate vaccines, natural protein-based nanoparticles well suited for multivalent antigen presentation and enhanced immune stimulation to elicit potent humoral and cellular immune responses are currently being investigated. This mini-review presents recent innovations in protein-based nanoparticle vaccines against SARS-CoV-2. The design and strategy of displaying antigenic domains, including spike protein, receptor-binding domain (RBD), and other domains on the surface of various protein-based nanoparticles and the performance of the developed nanoparticle-based vaccines are highlighted. In the final part of this review, we summarize and discuss recent advances in clinical trials and provide an outlook on protein-based nanoparticle vaccines.
Keywords: SARS-CoV-2; nanomedicine; nanovaccine; protein nanoparticles; protein-based nanotechnology; vaccines.
. 2021 Dec 14;22(24):13445.
doi: 10.3390/ijms222413445.
Protein-Based Nanoparticle Vaccines for SARS-CoV-2
Hyo-Dong Sung[SUP] 1 [/SUP], Nayeon Kim[SUP] 1 [/SUP], Yeram Lee[SUP] 1 [/SUP], Eun Jung Lee[SUP] 1 [/SUP]
Affiliations
- PMID: 34948241
- DOI: 10.3390/ijms222413445
Abstract
The pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has upended healthcare systems and economies around the world. Rapid understanding of the structural biology and pathogenesis of SARS-CoV-2 has allowed the development of emergency use or FDA-approved vaccines and various candidate vaccines. Among the recently developed SARS-CoV-2 candidate vaccines, natural protein-based nanoparticles well suited for multivalent antigen presentation and enhanced immune stimulation to elicit potent humoral and cellular immune responses are currently being investigated. This mini-review presents recent innovations in protein-based nanoparticle vaccines against SARS-CoV-2. The design and strategy of displaying antigenic domains, including spike protein, receptor-binding domain (RBD), and other domains on the surface of various protein-based nanoparticles and the performance of the developed nanoparticle-based vaccines are highlighted. In the final part of this review, we summarize and discuss recent advances in clinical trials and provide an outlook on protein-based nanoparticle vaccines.
Keywords: SARS-CoV-2; nanomedicine; nanovaccine; protein nanoparticles; protein-based nanotechnology; vaccines.